Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $1.4 billion.

  • Madrigal Pharmaceuticals' Liabilities and Shareholders Equity rose 2694.51% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 1336.88%. This contributed to the annual value of $1.0 billion for FY2024, which is 6271.2% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Liabilities and Shareholders Equity of $1.4 billion as of Q3 2025, which was up 2694.51% from $1.0 billion recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $1.4 billion for Q3 2025, and its period low was $158.6 million during Q3 2022.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $332.4 million (2023), whereas its average is $598.0 million.
  • In the last 5 years, Madrigal Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 4793.38% in 2022 and then skyrocketed by 35101.99% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $273.3 million in 2021, then surged by 32.65% to $362.6 million in 2022, then skyrocketed by 76.67% to $640.5 million in 2023, then skyrocketed by 62.71% to $1.0 billion in 2024, then soared by 30.72% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.4 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $996.6 million in Q1 2025.